Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2022 Earnings Conference Call April 26, 2022 9:00 AM ET Company Participants Lauren Morris ??? Director-Investor Relations August Troendle ??? Chief Executive Officer Jesse Geiger ??? President Kevin Brady ??? Chief Financial Officer Conference Call Participants Dave Windley ??? Jefferies Eric Coldwell ??? Baird Christine Rains ??? William Blair Paul Knight ??? KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2022 Earnings Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other jurisdicti ...

Financial Data and Key Metrics Changes - Revenue for Q4 2021 was $308.6 million, representing an 18.8% year-over-year increase. Full year 2021 revenue was $1.142 billion, a 23.4% increase over 2020 [11][15] - EBITDA for Q4 2021 was $61.4 million, a 2% increase from $60.2 million in Q4 2020. Full year 2021 EBITDA increased 18.8% to $223.1 million compared to $187.8 million in 2020 [16] - Net income for Q4 2021 was $50 million, compared to $50.9 million in the prior year period. Full year 2021 net income was $181.8 million, up from $145.4 million in 2020 [17] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q4 increased 27.9% year-over-year to $458.7 million, resulting in a net book-to-bill ratio of 1.49% [12] - For the full year 2021, net new business awards were $1.6 billion, an increase of 37.1%, with an ending backlog of approximately $2 billion, up 29.5% from the prior year [12] Market Data and Key Metrics Changes - Overall, COVID-19 related work represented only 2.2% of revenue and less than 1% of backlog for 2021 [13] - Backlog conversion in Q4 was 16.7% of beginning backlog, with approximately $1.04 billion of backlog projected to convert to revenue in the next 12 months [13] Company Strategy and Development Direction - The company is monitoring biotech funding and wage inflation closely, with wage inflation expected to be a headwind to margins [8][9] - The company anticipates maintaining a strong growth trajectory despite a decline in RFP dollar volume [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business environment, stating that despite a decline in RFPs, there are no significant signs of client hesitancy or funding issues [8][25] - The company reaffirmed its 2022 guidance, forecasting total revenue between $1.4 billion and $1.46 billion, representing growth of 22.6% to 27.8% over 2021 [20][21] Other Important Information - The company ended Q4 with $461 million in cash, no outstanding debt, and $50 million of undrawn capacity on its revolving line of credit [19] - The Board approved an increase of $300 million to the current share repurchase program [19] Q&A Session Summary Question: Are there signs of client hesitancy due to RFP decline? - Management indicated no significant signs of client hesitancy or funding issues despite the decline in RFPs [25] Question: How is the company addressing patient diversity in clinical trials? - Management acknowledged the importance of patient diversity and stated it is a consideration in site selection [26] Question: Are there changes in recruitment strategies due to wage inflation? - Management confirmed that recruitment strategies remain intact despite rising wage levels [27] Question: Are contracts changing in response to inflation? - Management stated that contract structures remain the same, with wage inflation assumptions included but not changed [32] Question: What are the thoughts on deploying cash on the balance sheet? - Management reiterated a consistent capital allocation strategy focused on organic growth and opportunistic share repurchases [35]

| --- | --- | --- | |-------|-------|-------| | | | | | | | | FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results, the ant ...

[PART I — FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Unaudited financial statements for Q3 2021 show total assets increased to **$1.58 billion**, with revenue growing **28.3%** to **$295.6 million** and net income reaching **$48.6 million**, supported by strong operating cash flow Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $398,387 | $277,766 | | Total current assets | $641,220 | $473,651 | | Total assets | $1,577,143 | $1,390,677 | | **Liabilities & Equity** | | | | Total current liabilities | $517,182 | $440,110 | | Total liabilities | $679,058 | $584,898 | | Total shareholders' equity | $898,085 | $805,779 | Condensed Consolidated Statements of Operations Highlights (in thousands, except per share) | Metric | Q3 2021 | Q3 2020 | YTD 2021 | YTD 2020 | | :--- | :--- | :--- | :--- | :--- | | Revenue, net | $295,567 | $230,373 | $833,825 | $666,247 | | Income from operations | $53,713 | $46,422 | $143,760 | $112,054 | | Net income | $48,574 | $41,460 | $131,814 | $94,518 | | Diluted EPS | $1.29 | $1.09 | $3.49 | $2.50 | Condensed Consolidated Statements of Cash Flows Highlights (Nine Months Ended, in thousands) | Cash Flow Activity | Sep 30, 2021 | Sep 30, 2020 | | :--- | :--- | :--- | | Net cash provided by operating activities | $192,433 | $153,178 | | Net cash used in investing activities | ($22,248) | ($23,480) | | Net cash used in financing activities | ($46,884) | ($42,074) | - The Board of Directors increased the stock repurchase program authorization to **$300.0 million**, with **377,783 shares** repurchased for **$62.1 million** during the nine months ended September 30, 2021[20](index=20&type=chunk) - Significant revenue was recognized from related parties, including **$18.3 million** from CinRx Pharma and **$5.6 million** from LIB Therapeutics, for the nine months ended September 30, 2021[50](index=50&type=chunk)[51](index=51&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Strong financial performance is attributed to growth in key therapeutic areas, with backlog increasing **29.0%** to **$1.85 billion** and Q3 revenue rising **28.3%** to **$295.6 million**, supported by a strong liquidity position of **$398.4 million** in cash Key Performance Metrics (in millions) | Metric | Q3 2021 | Q3 2020 | YTD 2021 | YTD 2020 | | :--- | :--- | :--- | :--- | :--- | | Net New Business Awards | $408.0 | $315.4 | $1,151.7 | $816.4 | - Backlog increased by **29.0%** to **$1.85 billion** as of September 30, 2021, with an expected conversion of **$1.005 billion to $1.025 billion** to revenue over the next twelve months[77](index=77&type=chunk) - Revenue growth for the three and nine months ended September 30, 2021, was primarily driven by expansion in Oncology, Metabolic, and Central Nervous System therapeutic areas[90](index=90&type=chunk) - The company maintains a strong liquidity position with **$398.4 million** in cash and cash equivalents and **$49.8 million** available under its credit facility, with no outstanding debt as of September 30, 2021[97](index=97&type=chunk)[98](index=98&type=chunk)[107](index=107&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) There have been no material changes to the company's quantitative and qualitative disclosures about market risk since the fiscal year ended December 31, 2020 - No material changes have occurred in the company's market risk disclosures since the last annual report[114](index=114&type=chunk) [Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2021, with no material changes to internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of the end of the period[116](index=116&type=chunk) - No material changes occurred in the company's internal control over financial reporting during the third quarter of 2021[119](index=119&type=chunk) [PART II — OTHER INFORMATION](index=30&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in incidental legal proceedings not expected to have a material adverse effect on its financial statements - The company is party to incidental legal proceedings not expected to have a material adverse effect on its financial statements[120](index=120&type=chunk) [Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) No significant changes have occurred in the risk factors previously disclosed in the company's 2020 Annual Report on Form 10-K - No significant changes have been made to the risk factors disclosed in the company's 2020 Annual Report on Form 10-K[121](index=121&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=30&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q3 2021, the company repurchased **34,624 shares** for approximately **$5.9 million** and issued securities to employees via stock option exercises exempt from registration Share Repurchases in Q3 2021 | Metric | Value | | :--- | :--- | | Total Shares Purchased | 34,624 | | Average Price Paid per Share | $171.50 | | Total Value of Repurchases | ~$5.9 million | - All share repurchases were executed pursuant to established Rule 10b5-1 trading plans[122](index=122&type=chunk) [Defaults Upon Senior Securities](index=32&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - No defaults upon senior securities were reported[127](index=127&type=chunk) [Mine Safety Disclosures](index=32&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This item is not applicable[128](index=128&type=chunk) [Other Information](index=32&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this period - No other information was reported for this period[129](index=129&type=chunk) [Exhibits](index=32&type=section&id=Item%206.%20Exhibits) This section references the Exhibit Index, listing all exhibits filed or furnished as part of the quarterly report - The exhibits listed in the accompanying Exhibit Index are filed or furnished as part of this report[130](index=130&type=chunk)

Medpace Holdings, Inc. (NASDAQ:MEDP) Q3 2021 Earnings Conference Call October 26, 2021 9:00 AM ET Company Participants Lauren Morris - Director of Investor Relations August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants John Kreger - William Blair Donald Hooker - KeyBanc Dave Windley - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Medpace Third Quarter 2021 Earnings Conference Call [Operator Instructions]. As a reminder, this call may be record ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0434904 (State or other jurisd ...

Medpace Holdings, Inc. (NASDAQ:MEDP) Q2 2021 Earnings Conference Call July 27, 2021 9:00 AM ET Company Participants Lauren Morris - Associate Director of IR August Troendle - President and CEO Jesse Geiger - CFO and COO, Laboratory Operations Kevin Brady - Executive Director of Finance Conference Call Participants Justin Lin - William Blair Dave Windley - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Medpace Second Quarter 2021 Earnings Conference Call. At this time, all participants ...

[PART I — FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for Q1 2021, including balance sheets, statements of operations, and cash flows, with accompanying notes Condensed Consolidated Statements of Operations (Q1 2021 vs Q1 2020) | (Amounts in thousands, except per share amounts) | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | **Revenue, net** | **$259,965** | **$230,879** | | Income from operations | $47,599 | $35,504 | | **Net income** | **$43,306** | **$28,954** | | Diluted EPS | $1.14 | $0.76 | Condensed Consolidated Balance Sheets Highlights | (Amounts in thousands) | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | Cash and cash equivalents | $332,877 | $277,766 | | Total current assets | $533,380 | $473,651 | | **Total assets** | **$1,451,360** | **$1,390,677** | | Total current liabilities | $447,306 | $440,110 | | **Total liabilities** | **$592,433** | **$584,898** | | **Total shareholders' equity** | **$858,927** | **$805,779** | Condensed Consolidated Statements of Cash Flows (Q1 2021 vs Q1 2020) | (Amounts in thousands) | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Net cash provided by operating activities | $57,319 | $49,148 | | Net cash used in investing activities | ($9,651) | ($5,522) | | Net cash provided by (used in) financing activities | $9,102 | ($40,445) | | **Increase in cash, cash equivalents, and restricted cash** | **$55,111** | **$2,079** | - As of March 31, 2021, **$102.6 million** remained authorized for share repurchases, with no repurchases in Q1 2021, contrasting with **$43.2 million** for **661,637 shares** in Q1 2020[21](index=21&type=chunk) - The company had approximately **$1.8 billion** in remaining performance obligations for active projects as of March 31, 2021[35](index=35&type=chunk) Revenue by Therapeutic Area (Q1 2021 vs Q1 2020) | Therapeutic Area | Q1 2021 Revenue (in thousands) | Q1 2020 Revenue (in thousands) | | :--- | :--- | :--- | | Oncology | $79,138 | $69,212 | | Other | $68,938 | $50,569 | | Metabolic | $32,495 | $36,075 | | AVAI | $30,820 | $25,147 | | Central Nervous System | $24,812 | $23,977 | | Cardiology | $23,762 | $25,899 | | **Total revenue** | **$259,965** | **$230,879** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=16&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2021 financial results, highlighting a **12.6% increase in net revenue** to **$260.0 million** and a significant rise in net income, alongside key performance metrics and liquidity Key Performance Metrics (Q1 2021 vs Q1 2020) | Metric | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Net new business awards | $356.2 million | $246.9 million | | Backlog (as of March 31) | $1,631.8 million | $1,294.2 million | - The company expects to convert approximately **$850 million to $870 million** of its backlog to net revenue over the next twelve months[76](index=76&type=chunk) - The COVID-19 pandemic continues to cause temporary disruptions, primarily impacting physical access to sites, patient enrollment, and trial start-up activities[82](index=82&type=chunk) - Net revenue increased by **$29.1 million (12.6%)** in Q1 2021 compared to Q1 2020, driven by growth in Oncology, AVAI, and other therapeutic areas[86](index=86&type=chunk) - The effective tax rate decreased to **10.7%** in Q1 2021 from **20.6%** in Q1 2020, primarily due to increased tax benefits from FDII and share-based compensation[92](index=92&type=chunk) - The company maintained a strong liquidity position with **$332.9 million** in cash and cash equivalents and **$49.8 million** available under its credit facility as of March 31, 2021[93](index=93&type=chunk)[94](index=94&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes have occurred in the company's quantitative and qualitative market risk disclosures since the 2020 Annual Report on Form 10-K - No material changes have occurred in the company's market risk disclosures compared to the 2020 Form 10-K[109](index=109&type=chunk) [Controls and Procedures](index=23&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2021, with no material changes to internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2021[111](index=111&type=chunk) - No changes in internal control over financial reporting occurred during Q1 2021 that materially affected, or are reasonably likely to materially affect, these controls[113](index=113&type=chunk) [PART II — OTHER INFORMATION](index=24&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=24&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in incidental legal proceedings not expected to materially affect its financial statements - The company is involved in legal proceedings incidental to its business, which are not expected to have a material adverse effect on its financial statements[114](index=114&type=chunk) [Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) No significant changes have occurred to the risk factors previously disclosed in the 2020 Annual Report on Form 10-K - No significant changes have occurred to the risk factors disclosed in the 2020 Annual Report on Form 10-K[115](index=115&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the issuance of common stock from employee stock option exercises in Q1 2021, exempt from registration under Rule 701 - During Q1 2021, employees exercised **223,758 stock options** under the 2014 Equity Incentive Plan for approximately **$3.4 million**[117](index=117&type=chunk) - These issuances were exempt from registration under Rule 701 of the Securities Act of 1933 as part of employee benefit plans[117](index=117&type=chunk) [Defaults Upon Senior Securities](index=25&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities during the period - None[119](index=119&type=chunk) [Mine Safety Disclosures](index=25&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[120](index=120&type=chunk) [Other Information](index=26&type=section&id=Item%205.%20Other%20Information) The company reports no other information to be disclosed for the period - None[121](index=121&type=chunk) [Exhibits](index=26&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the quarterly report, including a loan agreement amendment, CEO/CFO certifications, and Inline XBRL documents - Exhibits filed with the report include an amendment to the Loan Agreement, CEO and CFO certifications (Rule 13a-14(a) and Section 1350), and Inline XBRL data files[122](index=122&type=chunk)[124](index=124&type=chunk)

Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2021 Earnings Conference Call April 27, 2021 9:00 AM ET Company Participants Kevin Brady - Executive Director of Finance August Troendle - President and CEO Jesse Geiger - CFO and COO of Laboratory Operations Conference Call Participants Sandy Draper - Truist Securities John Kreger - William Blair Dave Windley - Jefferies Erin Wright - Credit Suisse Donald Hooker - KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2021 Earnings ...